Takeda Pharmaceutical acquires Nycomed

Japan-based Takeda Pharmaceutical has reached an agreement with the shareholders of Swiss pharmaceuticals company Nycomed in which Takeda will acquire the Zurich-headquartered company for €9.6bn (£8.5bn) on a cash-free, debt-free basis.

The transaction is expected to be completed within 90 to 120 days, making it a wholly owned subsidiary of Takeda, excluding Nycomed’s US dermatology business.